Pharma Focus Asia

Panbela Announces Regain of Worldwide Rights to Develop and Commercialise FlynpoviTM

Tuesday, April 11, 2023

Panbela Therapeutics announced that it has regained the North American rights to develop and commercialise Flynpovi (the combination of CPP-1X (eflornithine) and sulindac) in patients with familial adenomatous polyposis (FAP).

The new FAP registration trial will have the potential to provide a nonsurgical treatment option to both physicians and patients with FAP.

Flynpovi has the potential to make a meaningful difference for patients with FAP by bringing this innovative treatment to market. The renew of worldwide rights to Flynpovi for FAP patients, and internal expertise, experience with health authorities, relationship with FAP experts throughout the US and Europe and commitment to FAP patients and their families, in combination with the positive results from the FAP-310 trial, will provide a solid foundation for designing and executing a successful registration trial that will have the potential to impact patients with FAP globally.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024